Advances in targeted therapies: TNF blockade in clinical practice F C BREEDVELD, J R KALDEN, and J S SMOLEN Ann Rheum Dis 1999; 58 (Supplement 1 ): i1. [Extract] [Full text] [PDF] [Request Permissions]

	Access to disease modifying treatments for rheumatoid arthritis patients D E FURST, F C BREEDVELD, G-R BURMESTER, L CROFFORD, P EMERY, M FELDMAN, J R KALDEN, A KAVANAUGH, E KEYSTONE, P E LIPSKY, R N MAINI, L MORELAND, J S SMOLEN, L VAN DE PUTTE, T VISCHER, M WEINBLATT, and M WEISSMAN Ann Rheum Dis 1999; 58 (Supplement 1 ): i129-i130. [Extract] [Full text] [PDF] [Request Permissions]

	Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors Bryant G Darnay and Bharat B Aggarwal Ann Rheum Dis 1999; 58 (Supplement 1 ): i2-i13. [Extract] [Full text] [PDF] [Request Permissions]
	DAP kinase and DAP-3: novel positive mediators of apoptosis Adi Kimchi Ann Rheum Dis 1999; 58 (Supplement 1 ): i14-i19. [Extract] [Full text] [PDF] [Request Permissions]
	Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis Cornelis L Verweij Ann Rheum Dis 1999; 58 (Supplement 1 ): i20-i26. [Extract] [Full text] [PDF] [Request Permissions]
	The rationale for the current boom in anti-TNF treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF and minimise hazards? Marc Feldmann, Jan Bondeson, Fionula M Brennan, Brian M J Foxwell, and Ravinder N Maini Ann Rheum Dis 1999; 58 (Supplement 1 ): i27-i31. [Abstract] [Full text] [PDF] [Request Permissions]
	The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease George Kollias, Eleni Douni, George Kassiotis, and Dimitris Kontoyiannis Ann Rheum Dis 1999; 58 (Supplement 1 ): i32-i39. [Abstract] [Full text] [PDF] [Request Permissions]
	Role of tumour necrosis factor  in experimental arthritis: separate activity of interleukin 1 in chronicity and cartilage destruction Wim B van den Berg, Leo A B Joosten, George Kollias, and Fons A J van de Loo Ann Rheum Dis 1999; 58 (Supplement 1 ): i40-i48. [Abstract] [Full text] [PDF] [Request Permissions]
	Tumour necrosis factor and other cytokines in murine lupus Argyrios N Theofilopoulos and Brian R Lawson Ann Rheum Dis 1999; 58 (Supplement 1 ): i49-i55. [Extract] [Full text] [PDF] [Request Permissions]
	Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis R N Maini, P C Taylor, E Paleolog, P Charles, S Ballara, F M Brennan, and M Feldmann Ann Rheum Dis 1999; 58 (Supplement 1 ): i56-i60. [Extract] [Full text] [PDF] [Request Permissions]
	Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF treatment Gregory Harriman, Lesley K Harper, and Thomas F Schaible Ann Rheum Dis 1999; 58 (Supplement 1 ): i61-i64. [Extract] [Full text] [PDF] [Request Permissions]
	Etanercept: therapeutic use in patients with rheumatoid arthritis Leslie Garrison and Neil D McDonnell Ann Rheum Dis 1999; 58 (Supplement 1 ): i65-i69. [Abstract] [Full text] [PDF] [Request Permissions]
	Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7 Joachim Kempeni Ann Rheum Dis 1999; 58 (Supplement 1 ): i70-i72. [Extract] [Full text] [PDF] [Request Permissions]
	PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases Carl K Edwards, III Ann Rheum Dis 1999; 58 (Supplement 1 ): i73-i81. [Abstract] [Full text] [PDF] [Request Permissions]
	Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? C Bombardier and A Maetzel Ann Rheum Dis 1999; 58 (Supplement 1 ): i82-i85. [Abstract] [Full text] [PDF] [Request Permissions]
	Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis James F Fries Ann Rheum Dis 1999; 58 (Supplement 1 ): i86-i89. [Extract] [Full text] [PDF] [Request Permissions]
	FDA perspective on anti-TNF treatments William D Schwieterman Ann Rheum Dis 1999; 58 (Supplement 1 ): i90-i91. [Extract] [Full text] [PDF] [Request Permissions]
	European regulatory aspects on new medicines targeted at treatment of rheumatoid arthritis Gottfried Kreutz Ann Rheum Dis 1999; 58 (Supplement 1 ): i92-i95. [Extract] [Full text] [PDF] [Request Permissions]
	Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist Barry Bresnihan Ann Rheum Dis 1999; 58 (Supplement 1 ): i96-i98. [Extract] [Full text] [PDF] [Request Permissions]
	Interleukin 10 treatment for rheumatoid arthritis E William St Clair Ann Rheum Dis 1999; 58 (Supplement 1 ): i99-i102. [Extract] [Full text] [PDF] [Request Permissions]
	Clinical implications of tumour necrosis factor  antagonism in patients with congestive heart failure Guillermo Torre-Amione, Sonny S Stetson, and John A Farmer Ann Rheum Dis 1999; 58 (Supplement 1 ): i103-i106. [Extract] [Full text] [PDF] [Request Permissions]
	Immunomodulation by thalidomide and thalidomide analogues Laura G Corral and Gilla Kaplan Ann Rheum Dis 1999; 58 (Supplement 1 ): i107-i113. [Extract] [Full text] [PDF] [Request Permissions]
	Anti-TNF antibody treatment of Crohn's disease S J H van Deventer Ann Rheum Dis 1999; 58 (Supplement 1 ): i114-i120. [Extract] [Full text] [PDF] [Request Permissions]
	The role of TNF and lymphotoxin in demyelinating disease Christopher Lock, Jorge Oksenberg, and Lawrence Steinman Ann Rheum Dis 1999; 58 (Supplement 1 ): i121-i128. [Extract] [Full text] [PDF] [Request Permissions]

This supplement was made possible by unrestricted educational grants from Amgen (USA), Centocor (USA), Immunex (USA), Knoll (Germany), Schering-Plough (USA), and Wyeth-Ayerst (USA)

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.